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ABSTRACT:  Based on N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-
2-yl)methyl)-N-methylprop-2-yn-1-amine (II), and QSAR predictions, in this work we 
have designed, synthesized, and evaluated a number of new indole derivatives from 
which we have identified N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-
yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine (2) as a new cholinesterase and 
monoamine oxidase dual inhibitor. 
 
Key Words: Drug design, QSAR, Synthesis, Biological evaluation, Multipotent 
Molecules, MAO/ChE Inhibitors, PAMPA-BBB, Molecular modeling, ADMET, 
Alzheimer’s disease. 
 
 
 
INTRODUCTION 
 
Alzheimer's disease (AD) is an age-related neurodegenerative disorder that accounts for 
approximatively 70% of adult dementia.1 Worldwide, it is estimated that 40 million 
people suffer from AD, and the prevalence of AD is expected to rise significantly in the 
next decades, as the average age of the population increases.2 AD is characterized by a 
progressive memory loss, a decline in language skills and other cognitive impairments.3 
Although the etiology of AD is not completely known, common hallmarks, such as 
amyloid-β (Aβ)4 deposits, τ-protein aggregation,5 and oxidative stress,6 are thought to 
play key roles in the pathophysiology of the disease.7 In  addition, the selective loss of 
cholinergic neurons in AD results in a deficit of acetylcholine (ACh) in specific brain 
regions that mediate learning and memory.8 However, alterations in other 
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neurotransmitter systems, specially serotoninergic, and dopaminergic, are also thought 
to be responsible for the behavioural disturbances observed in AD patients.9   
Monoamine oxidase (MAO; EC 1.4.3.4), the enzyme that catalyses the oxidative 
deamination of a variety of biogenic and xenobiotic amines,10 is also an important target 
to be considered for the treatment of specific features of AD. MAO exists as two 
distinct enzymatic isoforms, MAO-A and MAO-B, based on their substrate and 
inhibitor specificities.11 MAO-A preferentially deaminates serotonin, adrenaline and 
noradrenaline and is selectively and irreversibly inhibited by clorgyline. In contrast, 
MAO-B preferentially deaminates β-phenylethylamine and benzylamine and is 
irreversibly inhibited by l-deprenyl.12 Selective inhibitors for MAO-A are effective 
antidepressants, whereas MAO-B inhibitors are useful in the treatment of Parkinson’s 
disease (PD)13 and might also be valuable for the treatment of AD.14 In fact, MAO-B 
inhibitors are also currently in clinical trials for the treatment of AD because an 
increased level of MAO-B has been detected in the plaque-associated astrocytes of 
brains from AD patients.15 
At present, there are three FDA-approved drugs (donepezil, galantamine and 
rivastigmine)16,17 that improve AD symptoms by inhibiting acetylcholinesterase (AChE; 
E.C.1.1.1.7), i.e. the enzyme responsible for the hydrolysis of ACh, and, thereby, raising 
ACh content in the synapsis. Apart from the beneficial palliative properties of AChE 
inhibitors in AD,18,19 cholinergic drugs have shown little efficacy to prevent the 
progression of the disease. Consequently, there is no efficient therapy to cure, stop or 
even slow the progression of the disease; therefore, effective therapeutics are urgently 
sought and needed.  
The failure to find such a drug or treatment is possibly due to the multifactorial 
nature of AD. Thus, a single drug that acts on a specific target to produce the desired 
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clinical effects might not be suitable for the complex nature of AD. Accondingly, the 
multi-target-directed ligand (MTDL) approach20-22 has been the subject of increasing 
attention by many research groups, which have developed a variety of compounds 
acting on very diverse targets.23-26 
We have previously reported N-((5-(benzyloxy)-1H-indol-2-yl)methyl)prop-2-
yn-1-amine (I)27 (Figure 1) as a potent and selective propargylamine-containing MAO-
B inhibitor (MAOBI) possessing neuroprotective properties that, unlike l-deprenyl does 
not generate amphetamines when metabolised and possesses anti-apoptotic properties.28 
Next we used I as hit compound with therapeutic potential for the treatment of 
neurodegeneratyive diseases, and started a project targeted to finding an improved lead 
compound.  
As a result of this effort, we found that N-((5-(3-(1-benzylpiperidin-4-
yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (II, Figure 1) 
is a multipotent drug able to inhibit human AChE (hAChE) and human 
butyrylcholinesterase (hBuChE), showing inhibition of human MAO-A and human 
MAO-B (hMAO-A, hMAO-B).29 The kinetic analysis demonstrated that compound II 
is not only a reversible inhibitor of both hAChE and hBuChE with micromolar affinity, 
but a highly potent irreversible inhibitor of hMAO-A, similarly to clorgyline.30 The 
crystal structure of human MAO-B in complex with compound II highlighted the 
covalent adduct formed with the flavin N5 atom which, based on the spectral changes, 
occurs also with the MAO-A cofactor.30 Hybrid II inhibited Αβ1-42 self-aggregation 
more efficiently than that of Αβ1-40, limiting the formation of fibrillar and oligomeric 
species,31 and completely blocked the aggregation mediated by AChE of both Αβ1-42 
and Αβ1-40. Interestingly, compound II significantly reduced Αβ1-42-mediated toxicity in 
SH-SY5Y human neuroblastoma cells, and showed a significant ability to capture free-
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radical species in vitro, as well as a potent effect in preventing the Αβ1-42 induced 
depletion of catalase and SOD-1.31,32 Finally, compound II  is able to cross the blood 
brain barrier in vivo.33 Overall, these data indicate that hybrid II is the desired lead 
compound in our search for neurodegenerative diseases therapy. 
 
Figure 1. Schematic structural and 
functional modifications in compounds I 
and II leading to the new target 
molecules 1-19. 
 
Based on these results, we started a lead compound optimization program, 
whose results are described now in this manuscript. From this study, N-methyl-N-((1-
methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-
yn-1-amine (2) has emerged as a permeable, potent, irreversible, and quite selective 
hMAO-A inhibitor (MAOAI) in the nanomolar range, showing also moderate and 
almost equipotent hAChE vs  hBuChE inhibition power. 
RESULTS AND DISCUSSION 
Design. In figure 1 we show the modifications in compounds I and II which have 
resulted into the new nineteen molecules that we have synthesized. Our selection was 
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based on QSAR analysis (see below), and simple functional changes on compounds II  
(Figure 2) and I (Figure 3).  
 
Figure 2. Compounds 1-12 synthesized and 
designed from compound II. 
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Figure 3. Synthesized compounds 13-
19 designed from compound I. 
. 
As depicted, the N-benzyl motif in compound II has been eliminated (1), or 
modified incorporating different substituents in the phenyl ring, such as o-MeC6H5CH2 
(2), p-CNC6H5CH2 (3), and N-[(8-O-methyl- or 8-O-(N,N´-dimethylcarbamoyl)]5-
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methylen]quinolone (4 and 5) (Figure 2). Taking into account the structure, inhibition 
power and selectivity of compound I for MAO B,27 the N(1)Me in compound II has 
been replaced by a N1(H) leading to 6; the N(1)Me and 
(indole)C(2)CH2N(Me)CH2C≡CH in hybrid II has been replaced by a N1(H) and 
(indole)C(2)CH2N(H)CH2C≡CH in 7 (Figure 2); compound 8 is like 7 (Figure 2), but 
the acetylene has been substituted by a vinyl group. Compounds 9 and 10 (Figure 2) are 
the N-benzyl- and N-phenyl-1,2,3-triazole derivatives,34 respectively, of compound II. 
Similarly, compounds 11 and 12 (Figure 2) result from hybrid II by eliminating the 
C(2)CH2N(Me)CH2C≡CH side chain by CH2OH, and CO2Et,35 respectively, and in both 
cases we have replaced the N(1)Me group  by N(1)H.  
Regarding compound I,27 related transformations have afforded compounds 13-
16 (Figure 3). Compounds 17-19 (Figure 3) are ladostigil/rasagiline-like carbamates, 
where we wanted to explore the known ability of compounds bearing this functional 
motif to inhibit ChEs.36 Results from recent MAO/ChE literature, such as the 
substitution of an acetylene by a triazole,34 or the use of a multifunctional chelator 
derived from 8-hydroxyquinoline,37 have been used to design molecules 5, 9, 10, 14, 
and 15 (Figures 2 and 3). 
 
QSAR analysis. The 3D-QSAR study has been carried out with main aim to explain 
and predict the binding on the active sites of human MAO-A, MAO-B, AChE, and 
BuChE enzymes based on the pharmacological activities27,31,35 previously observed for 
the lead-improving program work with multipotent compound II (Supporting 
Information), and the results are shown in table 1.  
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Table 1. Experimental and QSAR-predicted  
activities of novel MAO/ChE inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMPD 
Experimental 
IC50 (hMAO-A)a 
Predicted 
IC50 (MAO-A) 
2 6.3 ± 0.4 nM 3.9 nM 
4 10.3 ± 0.8 nM 218.8 nM 
5 257.6 ± 11.4 nM 306.2 nM 
14 310.6 ± 17.1 nM 3.2 µM 
13 630.1 ± 16.1 nM 23.7 µM 
CMPD 
Experimental 
IC50 (hMAO-B)a 
Predicted  
IC50 (MAO-B) 
2 183.6 ± 7.4 nM 100.7 nM 
13 164.7 ± 12.1 nM 662.2 nM 
5 196.3 ± 7.8 nM 38.8 µM 
14 273.1 ± 8.9 nM 58.5 µM 
4 7.9 ± 0.5 nM 73.1 µM 
CMPD 
Experimental 
IC50 (hAChE) 
Predicted 
IC50 (AChE) 
2 2.8 ± 0.1 µM 849.2 nM 
5 8.4 ± 0.9 µM 3.0 µM 
14 ** 4.0 µM 
4 *** 10.3 µM 
13 ** 11.1 µM 
CMPD 
Experimental 
IC50 (hBuChE) 
Predicted 
IC50 (BuChE) 
2 4.9 ± 0.2 µM 1.3 µM 
5 5.9 ± 0.4 µM 4.4 µM 
4 ** 9.8 µM 
14 ** 14.8 µM 
13 ** 202.8 µM 
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aAfter 15 min pre-incubation, so not directly comparable 
with the predicted IC50 values.                     
  ** Inactive at 100 µM (highest concentration tested). 
*** 100 µM inhibits the corresponding MAO activity by 
approximately 40-50%. At higher concentration the 
compounds precipitate.  
 
 
 
In the data set of previously characterised indole derivatives,27,31,35 the MAO-A 
pIC50 activity interval spanned 4 log units (3.07–9.10); for pIC50 (MAO-B) it was 5.6 
log units (4.00–10.60), for pIC50 (AChE) 4.2 log units (4.00-8.17), and pIC50 (BuChE) 
3.4 log units (4.00-7.44). The relatively wide pIC50 interval of the training set provide 
broad applicability domain for the 3D-QSAR models created. The 3D-QSAR (MAO A) 
model with two significant components (A= 2), R2: 0.94, leave-one-out cross validation 
Q2: 0.66, Training Set parameters (R2Observed vs. Predicted: 0.908 and RMSEE: 0.433), and 
Test Set parameters (R2Observed vs. Predicted: 0.809 and RMSEP: 0.617), was developed. The 
3D-QSAR (MAO B) model with two significant components (A=2), R2: 0.97 and leave-
one-out cross validation Q2: 0.85, Training Set parameters (R2Observed vs. Predicted: 0.957 
and RMSEE: 0.303), and Test Set parameters (R2Observed vs. Predicted: 0.787 and RMSEP: 
0.598), was formed. Similarly,the 3D-QSAR (AChE) model with three significant 
components (A=3), R2: 0.87 and leave-one-out cross validation Q2: 0.61, Training Set 
parameters (R2Observed vs. Predicted: 0.873 and RMSEE: 0.431), and Test Set parameters 
(R2Observed vs. Predicted: 0.539 and RMSEP: 0.661), was developed. The 3D-QSAR (BuChE) 
model with two significant components (A=2), R2: 0.92 and leave-one-out cross 
validation Q2: 0.72, Training Set parameters (R2Observed vs. Predicted: 0.922 and RMSEE: 
0.261), and Test Set parameters (R2Observed vs. Predicted: 0.657 and RMSEP: 0.521), was 
created.35 
The statistical parameters indicated that the 3D-QSAR (MAO-A, MAO-B, 
AChE, BuChE) models could be used for prediction of MAO-A, MAO-B, AChE, and 
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BuChE inhibiting activities for novel analogs of compounds I and II. Reliability of the 
activities predictions is strongly related to the type and extent of structural changes of 
the lead compounds.  
 3D-pharmacophores are derived from 3D-maps of interaction energies between 
the examined molecule and four chemical probes: DRY (which represent hydrophobic 
interactions), O (sp2 carbonyl oxygen, representing H-bond acceptor), N1 (neutral flat 
NH, like in amide, H-bond donor), and the TIP probe (molecular shape descriptor). The 
3D-pharmacophores for MAO-A and MAO-B inhibiting activities of compound II 
contain crucial favorable O-TIP/O-DRY/TIP-TIP/DRY-TIP interactions between the 
propargylamine moiety and the benzyl group. Therefore, substitution of the benzyl 
moiety of hybrid II with small groups, such as an o-Me in 2 (Figure 2), could enhance 
the MAO-A and MAO-B inhibiting activity of the examined compounds by facilitating 
the TIP-TIP/DRY-TIP favorable interactions. The 3D-QSAR study confirmed also 
previous experimental findings that the propargylamine moiety provides an essential 
positive influence on the MAO-A and MAO-B inhibiting activity.35,38,39  
 The 3D-pharmacophores for BuChE inhibiting activities of lead compound II 
contain specific unfavorable TIP-TIP/DRY-TIP interactions between the indole and the 
para position of the benzyl moieties. Therefore, substitution with bulky substituent at 
para position of the benzyl moiety, such as a cyano group in 3 (Figure 2), could 
decrease BuChE inhibiting activity of compound II derivatives (Table 1). The 3D-
pharmacophores for AChE inhibiting activities of compound II contain a crucial 
favourable O-O interaction between the piperidine ring and ortho positions of the 
benzyl group. Thus a small substituent at ortho position of the benzyl ring, such as the 
methyl group in compound 2 (Figure 2) could enhance AChE inhibiting activity of lead-
compound II (Table 1).   
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In addition to 2, compounds 4, 3, 13 and 14 have also been investigated by 
QSAR analysis, and their predicted IC50 values are also shown in table 1. The predicted 
IC50 values clearly suggest that: (a) compound II-donepezil type hybrids 2, 4, and 5, in 
this order, should be the most potent MAO-AI; (b) the compound I-like derivative 14 
should be a more potent inhibitor of MAO-A, AChE, and BuChE than 13; and (c) 2 
should be the most potent inhibitor against all four enzymes.  
Next, the designed compound II analogues were synthesized and examined for 
MAO/ChE inhibitory activity.  
 
Chemistry. The synthesis of the new molecules (Figures 2 and 3) has been achieved by 
standard or reported methods, in very efficient and short synthetic sequences, in good 
overall yields (see Supporting Information). All new molecules gave satisfactory 
analytical and spectroscopic data, in good agreement with their structures. 
 
Table 2. IC50 Values for the Inhibitory Effects of Test Compounds on the Enzymatic 
Activity for human MAO or ChE isoforms and Selectivity Ratios for MAO-B [IC50 
(MAO-A)]/[IC50 (MAO-B)] or for AChE ([IC50 (AChE)]/[IC50 (BChE)] a 
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a All IC50 values shown in this Table are the mean ± SD from five experiments. hMAO: IC50 values were 
determined after 15 min preincubation of inhibitor with the enzyme. hChE: IC50 values were determined after 10 
min preincubation of inhibitor with the enzyme.  Level of statistical significance: bP < 0.01 or cP < 0.05 versus the 
corresponding IC50 values obtained against MAO-B, as determined by ANOVA/Dunnett´s. d Ref. 23. ** Inactive 
at 100 µM (highest concentration tested). nd: not determined. 
 
 
Biological evaluation. The biological evaluation, comprising the hMAO-A/ hMAO-B, 
and hAChE/ hBuChE inhibition, has been carried out according to the protocols 
described in the Supporting Information, following the usual methods.40,41 In Table 1S 
(Supporting Information) we have shown the IC50 values for the inhibition of the 
MAOs and ChEs with all the nineteeen new compounds, using compounds I and II, re-
analyzed in this work42 as reference compounds. The established MAOI, clorgyline and 
CMPD hMAO-A  hMAO-B Ratio hAChE  hBuChE  Ratio 
2 
(MBA236) 6.3 ± 0.4 nM
b 183.6 ± 7.4 nM 0.03 2.8 ± 0.1 µM 4.9 ± 0.2 µM 0.57 
5 257.6 ± 11.4 nMc 196.3 ± 7.8 nM 1.3 8.4 ± 0.9 µM 5.9 ± 0.4 µM 1.4 
6 9.1 ± 0.7 µMc 35.1 ± 2.8 µM 0.26 15.4 ± 0.9 µM 7.1 ± 0.5 µM 2.2 
7 19.2 ± 1.3 µMc 33.6 ± 1.5 µM 0.57 4.9 ± 0.3 µM 7.3 ± 0.8 µM 0.67 
8  45.3 ± 1.6 µMc 21.3 ± 1.9 µM 2.1 4.6 ± 0.3 µM 40.6 ± 2.2 µM 0.11 
11 876.6 ± 25.2 nM 1.0 ± 0.02 µM 0.87 9.6 ± 0.08 µM 9.7 ± 0.7 µM 0.99 
12 9.1 ± 0.3 µM 13.5 ± 1.1 µM 0.67 13.6 ± 1.4 µM 31.2 ± 3.1 µM 0.43 
II 58.2 ± 1.2 nMa 1.2 ± 0.1 µM 0.05 3.4 ± 0.2 µM 3.3 ± 0.2 µM 1.03 
I 287.3 ± 11.2 nMb 4.1 ± 0.7 nM 70 ** **  
Clorgyline 4.7 ± 0.2 nMb 65.8 ± 1.6 µM 0.000071 ** ** 
 
l-Deprenyl 63.6 ± 1.3 µMb 18.2 ± 0.9 nM 3,494 ** **  
Donepezild nd nd  0.016 ± 0.001 µM 8.2  ±  0.2 µM	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l-deprenyl, and the ChEI, donepezil, are also reported for comparative purposes. Note 
that only seven compounds, 2, 5-8 11, and 12, were active simultaneously in the four 
enzymes (Table 2). As shown in table 1S, compound 6 is a moderate hMAO-AI and 
hBuChEI, in the high micromolar range, but shows very modest hMAO-B and hAChE 
inhibition power. 12 is almost equipotent with 6 for the hMAO-A and hAChE 
inhibition, but 2.6-fold more, and 4.4-fold less potent than 6, for the inhibition of 
hMAO-B and hBuChE, respectively. 7 is a poor hMAO-AI and hMAO-BI, but a 
moderate hAChEI and BuChEI, in the micromolar range. 8 is a quite poor hMAO-AI, 
hMAO-BI and hBuChEI, but a modest hAChEI. Furthermore, 5, and 11 were non-
selective, potent hMAOI in the low micromolar range, but moderate and equipotent 
ChE inhibitors.   
However, among all these products, as predicted by the QSAR analysis (see above), 
compound 2 (Table 2) was the most potent hMAO-A, hMAO-B AChE, and BuChE 
multipotent inhibitor found in this work. Compound 2 is a very potent, in the 
nanomoloar range, and selective hMAO-AI (with an apparent mixed inhibitor Ki = 7.5 ± 
0.9 nM), showing a potent and slightly selective hAChE inhibition profile (Ki = 1.3 ± 
0.5 µM), in the micromolar range. Compared with the reference compound II, the new 
compound 2 is 9.2-fold and 6.5-fold more potent hMAO-AI and hMAO-BI, 
respectively, 1.2-fold more potent hAChEI, and only 1.5-fold less potent hBuChEI. 
Comparing with compound I and the standard MAOIs, for the inhibition of MAO-A, 
compound 2 is 45-fold more potent than compound I, 1.3-fold less than clorgyline, and 
10095-fold more potent than l-deprenyl. Conversely, for the inhibition of MAO-B, 
compound 2 is 45-fold less, 358-fold more and 10-fold less potent than compound I, 
clorgyline and l-deprenyl, respectively.  
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Figure 4. Structure of compound 2, and its 
IC50 values for the inhibition of MAO and 
ChEs, compared with the reference 
compound II.  
To sum up, compound 2  is a multipotent molecule of MAO and ChE, showing a 
very attractive pharmacological profile, as a selective and very potent MAO-AI, with 
high MAO-B and potent hAChE/ hBuChE inhibition power. It must be also concluded 
that all our present and past efforts29 to transform compound I into a multipotent 
MAO/ChE compound, by transforming the benzyl group into the ChE donepezil-like 
pharmacophore have met with success, but at the cost of loosing significant MAO-B 
inhibition capacity. 
Taking into account these findings, we have performed further studies on the 
inhibition mechanism of action of compound 2.  
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Figure 5. Recovery of hMAO-A activity after dilution 
following incubation (30 min at room temperature) of 
the 100x-enzyme concentration with 10-fold IC50 
concentration of compound 2 or clorgyline. The control 
was carried out by pre-incubating in the absence of 
inhibitor and diluting in the same way. Results are 
expressed as percentage of control. Represented data 
are mean ± SD of five independent assays. 
 
Figure 6. Recovery of hMAO-B activity after dilution 
following incubation (30 min at room temperature) of the 
100x-enzyme concentration with 10-fold IC50 
concentration of compound 2 or l-deprenyl. The control 
was carried out by pre-incubating in the absence of 
inhibitor and diluting in the same way. Results are 
expressed as percentage of control. Represented data are 
mean ± SD of five independent assays. 
 
Figures 5 and 6 show the results of the reversibility test43 on hMAO. Compound 
2 binds as an irreversible inhibitor on both enzyme isoforms, maintaining near a 90% 
inhibition after the dilution of the pre-incubated mixture.  The IC50 decreased from 14.6 
± 1.2 nM in reversible conditions (no preincubation and substrate concentration 2xKm) 
to 6.3 ± 0.4 nM assayed with saturating substrate after a 15 min incubation.  
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Figure 7. Recovery of hAChE (grey column) and  
hBuChE (black column) activity after the dilution of 
the incubation (30 min at room temperature) of the 
100X-enzyme concentration and 10-fold IC50 of 
compound 2. The control was carried out by pre-
incubating in the absence of inhibitor and diluting in 
the same way. Results are expressed as percentage of 
control. Represented data are mean ± SD of five 
independent assays. 
 
Nevertheless, the recovery of ChE activity after compound was significantly 
greater (around 20%), allowing us to classify it as a slow inhibitor (Figure 7). Kinetic 
assays performed with this compound have shown ambiguous results, probably due to 
the low degree of reversibility of inhibition achieved on hAChE and hBuChE. As a 
result of the low reversibility, the pattern of the Lineweaver-Burk representation appears 
to indicate a mixed model for both enzymes (results not shown).  
With the aim of investigating compound 2 recognition with respect to either 
MAO-A, MAO-B, AChE and BuChE enzymes, molecular modeling studies have been 
carried out. The theoretical investigation has been focused on the ligand enzyme 
interaction and target structural perturbation produced by compound 2 comparing these 
information with respect to the same data coming from the related compound II 
(Supporting Information). Only one proposed structure was found for compound 2  in 
hMAO-A and two for hMAO-B, with a global miminum population equal to 96.11%. 
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Compounds II and 2 both adopted bent conformations in hMAO-A, but were linear in 
hMAO–B (Figure S1, Supporting Information). Overall, the interactions between 
compounds II, 2 and the MAOs are driven by both steric hindrance and hydrophobic 
contribution with an additional electrostatic term present in hMAO-A. Using the target 
RMSd matrix, each MD trajectory was clustered into nine groups. The visual inspection 
of the ten structures for each inhibitor with each enzyme clearly indicates the 
conformation stabilizing effect of the o-methyl group in hybrid 2 (Figure S4, 
Supporting Information).  
In this work we have designed a new and multipotent MAOI. MAOI are well 
known for showing diverse therapeutic potential as the result of combining selectivity 
and (ir)reversible modes of binding.15 MAO-AI have been used mostly in the treatment 
of depression and anxiety,44 and MAO-BI for the treatment of PD.45 Recent studies have 
shown that MAO-A is involved in the regulation of serotonin for ventricular remodeling 
via activation of the serotonin2A receptors.46 In the aged heart, the increased MAO-A 
concentrations results in high levels of oxygen peroxide leading to cardiomyocyte 
severe damage.47 A survey of the current literature on MAOIs shows also that one of the 
major reasons for designing new and specific inhibitors is to function as 
cardioprotectants for the age-dependent increase of MAO A in the heart.48 Although 
MAO-AIs enhance extracellular levels of dopamine produced from L-dopa, irreversible, 
and selective MAO-AI cannot be used in the PD therapy, because of  cardiovascular 
side effects.49 Another disadvantage of an irreversible MAO-AI is the hypertensive 
“cheese effect”,50 due to the predominance of MAO-A in the gut wall to metabolize 
tyramine in fermented foods such as cheese and beer. Hypertensive crises may be 
prevented by using reversible rather than irreversible MAO-AI, or tissue-specific 
inhibitors such as the brain-selective ladostigil.51 
 19 
 
Figure 8. Structures of ladostigil, and M30D.  
 
 
The cases of ladostigil52 and M30D53 (Figure 8) are of interest for this project 
and future possible endeavours, because both are ChE, MAO-A and MAO-B 
irreversible inhibitors with potential therapeutic applications as antidepressants, 
antiparkinson and anti-Alzheimer drugs.44 Ladostigil51 (Figure 8) was designed from 
rasagiline, a MAO-BI, bearing a propargylamine motif, responsible for the 
neuroprotective properties, and a carbamate group, affording ChE inhibitory activity. 
M30D53 (Figure 8) shows an inhibitory profile against ChE [hAChE IC50= 0.52 ± 0.07 
µM;	  hBuChE IC50= 44.90 ± 6.10	  µM] and against MAO [ratMAO-A: IC50= 0.0077	  ±	  0.0007 µM; ratMAO-B: IC50= 7.90	  ±	  1.34  µM] very similar the one observed for 2 
(Table 2), as well as other properties as potential drugs for treating AD. 
 
In Vitro Blood–Brain Barrier Permeation Assay. Finally, in order to evaluate the 
brain penetration we used the PAMPA-BBB method described by Di,54 and 
subsequently optimised by Rodríguez-Franco et al. for molecules with limited water-
solubility.55-57  
The in vitro permeability (Pe) value of compound 2 through a lipid extract of 
porcine brain was determined by using PBS: ethanol (70:30). In the same assay, 11 
commercial drugs of known CNS penetration were also tested and their experimental 
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values were compared to reported values, giving a good lineal correlation, Pe (exp.) = 
1.4442 Pe (bibl.) + 6.5263 (R2 = 0.95). From this equation and taking account the limits 
established by Di for BBB permeation,54 we found that compounds with permeability 
values above 12.3 10-6 cm s-1 could penetrate into the CNS. Derivative 2 showed Pe = 
14.4 ± 0.4 10-6 cm s-1 and thus, it could cross BBB by passive diffusion (Supporting 
Information). 
 
CONCLUSIONS 
In this paper we have reported the design, synthesis and biological evaluation of 
nineteen new donepezil-indolyl hybrids as multifunctional drugs able to bind MAO and 
ChE enzymes, using the MAO B inhibitor I hit, and the multipotent II hybrid lead as 
references for lead-optimization in order the discover a new lead-compound for deeper 
in vivo pre-clinical investigations targeted to neurological disorders. The QSAR-
designed compound II analogues have been synthesized and examined for MAO/ChE 
inhibitory activity. As shown in figure 4, the potent MAO/ChE inhibiting activity for 
the novel ligand 2 confirmed the quality of the optimized 3D-pharmacophores for use in 
future work to design novel donepezil-indolyl hybrids. We have found significant 
biological activity on the four enzymes studied in almost half of the synthesized 
structures. The most promising compound of the series, 2, acted as an irreversible 
hMAO-AI, potent in the nanomolar range, nine times more potent than the reference 
compound II, and 29-fold more selective for hMAO-A over hMAO-B. Inhibition of the 
ChEs by hybrid 2 is in the micromolar range, slightly better than compound II for 
hAChEs although slightly poorer for hBuChE.  Although we are confronted with 
unbalanced, highly preferred MAO vs ChE inhibition, the potency and desired balance 
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between targets in MTDL-based strategies is not known.58  Molecular modeling 
studies59 reported similar binding modes of compounds II and 2 in all the evaluated 
biological targets. The o-Me group in compound 2 improves the ligand recognition 
increasing the ligandenzyme hydrophobic interaction in hBuChE, and π-π stacking in 
hMAO-A, hMAO-B and hAChE. Thus, it is clear that simple modification of compound 
II, such as the incorporation of an o-methyl instead of a hydrogen in the phenyl ring of 
the N-benzylpiperidine motif, produces significant qualitative and quantitative 
pharmacological changes in the inhibition of MAO and ChE enzymes. Finally, the 
ADMET virtual analysis59 suggests that inhibitor 2 should not be hepatotoxic, not show 
hERG liability, and should present good drug-like characteristics similar to compound 
II, with a slightly better brain penetration ability, a prediction experimentally confirmed 
by the in vitro blood–brain barrier permeation assay.  
Consequently, we have fulfilled our initial expectations, that a new, easily 
available, permeable multipotent MAO inhibitor has been discovered. The related 
pharmacological properties with ladostigil, clearly support projected in vivo studies for 
proof of concept targeted to probe the suitability of compounds 2 and II to treat 
neurodegeneratives disorders such AD or PD.  
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